This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Renalytix plc

("Renalytix" or the "Company")

Investor Presentation and Revised Revenue Guidance

Revised forward guidance on expected long-term increase in revenue

LONDON and NEW YORK, 23 September 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that an updated corporate presentation will be available today for download from the Company's website at https://investors.renalytix.com/presentations/.

The corporate presentation includes revised forward guidance on the Company's expected revenue: $8.4m in FY26, $19.0m in FY27 and $42.0m in FY28 with the later years of FY27 and FY28 reflecting the anticipated positive revenue impact from Renalytix's recently announced collaboration agreement with Tempus AI, Inc. (Nasdaq: TEM) ("Tempus"). This revenue guidance compares to a prior outlook through FY27 calling for $8.5m in FY26, and $17.5m for FY27 as provided in the Company's Half Year Report on 18 March 2025.

The Board of Directors are currently considering the long-term positive impact of the Tempus collaboration and the Company will provide further updates regarding forward revenue guidance as appropriate, as the two parties execute implementation into hospital systems and other healthcare providers.

For further information, please contact:

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.